Dexcom (DXCM) awards 5,575 restricted stock units to director

Rhea-AI Filing Summary

Heller Bridgette P reported acquisition or exercise transactions in this Form 4 filing.

Dexcom Inc. director Bridgette P. Heller received an equity award of 5,575 restricted stock units (RSUs) of common stock. The RSU grant was made on May 28, 2026 at no cash cost to her and is compensation-related, not an open-market purchase. The RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 Annual Meeting of Stockholders. After this award, Heller directly holds 30,582 shares of Dexcom common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Heller Bridgette P

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,575	$0.00	--

Holdings After Transaction: Common Stock — 30,582 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 5,575 RSUs Transaction price: $0.00 per share Shares owned after grant: 30,582 shares +1 more

4 metrics

RSU grant size 5,575 RSUs Restricted stock unit award on May 28, 2026

Transaction price $0.00 per share Grant/award acquisition, no cash paid

Shares owned after grant 30,582 shares Direct Dexcom common stock holdings post-transaction

Vesting schedule Earlier of 1 year or 2027 meeting 100% of RSU award vests by 2027 Annual Meeting

Key Terms

restricted stock unit (RSU), Annual Meeting of Stockholders, contingent right

3 terms

restricted stock unit (RSU) financial

"Each share is represented by a restricted stock unit (RSU) that represents a contingent right"

A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.

Annual Meeting of Stockholders financial

"will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders"

contingent right financial

"represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heller Bridgette P

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		A		5,575(1)	A	$0	30,582	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Bridgette P. Heller	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Dexcom (DXCM) director Bridgette P. Heller report on this Form 4?

Bridgette P. Heller reported receiving a grant of 5,575 restricted stock units of Dexcom common stock. This is a compensation-related equity award, not an open-market share purchase or sale, and increases her direct holdings to 30,582 shares following the grant.

Is the Dexcom (DXCM) Form 4 transaction a stock purchase or sale?

The transaction is neither a market purchase nor a sale; it is a grant of 5,575 restricted stock units as compensation. The Form 4 uses code “A,” indicating a grant, award, or other acquisition rather than an open-market trade by the director.

When do Bridgette P. Heller’s Dexcom (DXCM) RSUs vest?

The 5,575 RSUs granted to Bridgette P. Heller vest 100% on the earlier of the one-year anniversary of the May 28, 2026 grant date or Dexcom’s 2027 Annual Meeting of Stockholders. Vesting must occur before the RSUs settle into common shares.

How many Dexcom (DXCM) shares does Bridgette P. Heller own after this RSU grant?

After the RSU award, Bridgette P. Heller directly holds 30,582 shares of Dexcom common stock. This figure, disclosed in the Form 4, reflects her direct ownership immediately following the 5,575 restricted stock unit grant on May 28, 2026.

Did Bridgette P. Heller pay anything for the Dexcom (DXCM) RSU grant?

The reported transaction price per share is $0.00, indicating Heller did not pay cash for the 5,575 RSUs. Such director equity awards are typically part of non-cash compensation, with value delivered through future settlement into Dexcom common shares.